BiomX’s (PHGE) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of BiomX (NYSEMKT:PHGE) in a report published on Monday, Benzinga reports. The firm currently has a $2.00 price target on the stock.

BiomX Trading Down 2.2 %

Shares of BiomX stock opened at $0.34 on Monday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.84 and a current ratio of 2.84. The stock’s fifty day simple moving average is $0.32 and its 200-day simple moving average is $0.31. The firm has a market cap of $18.72 million, a P/E ratio of -0.64 and a beta of 1.36.

BiomX Company Profile

BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).